文献速递瘢痕与激光创面修复

间充质干细胞条件培养基联合A型肉毒毒素治疗人增生性瘢痕

Combination of mesenchymal stem cell-conditioned medium and botulinum toxin type A for treating human hypertrophic scars.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2019-08-08

本研究在人增生性瘢痕成纤维细胞及瘢痕埋植裸鼠模型中,比较间充质干细胞条件培养基(MSC CM)与A型肉毒毒素(Botox)单用或联用的疗效。联用方案可下调I型胶原、III型胶原及α-SMA的mRNA和蛋白水平,抑制成纤维细胞增殖、促进凋亡并抑制收缩能力,在体内显著减轻瘢痕重量并改善胶原排列。结论提示联用优于单药治疗,值得进一步临床转化研究。

要点

  • MSC CM与Botox联用可下调HS成纤维细胞I、III型胶原及α-SMA表达。
  • 联用抑制HS成纤维细胞增殖、促进凋亡并减弱收缩能力。
  • 裸鼠模型中联用显著减轻瘢痕重量并改善胶原纤维排列。

核心结论

  • MSC CM与Botox联用较单药治疗对人增生性瘢痕表现出显著治疗效应,值得考虑临床转化。

研究设计与样本

  • 体外采用人增生性瘢痕来源成纤维细胞,分别给予DMEM、MSC CM、Botox单用或MSC CM联合Botox处理。
  • 体内采用人增生性瘢痕埋植裸鼠模型评估联合治疗的疗效。

主要发现

  • 联用方案下调HS成纤维细胞I型胶原、III型胶原及α-SMA的mRNA和蛋白水平。
  • 联用方案抑制HS成纤维细胞增殖活性、增加凋亡,并较MSC CM、Botox或DMEM单用显著抑制收缩能力。
  • 裸鼠模型中联用方案较其他组显著减轻瘢痕重量、促进细胞凋亡并减少α-SMA表达。
  • 联用方案显著改善胶原纤维的排列与沉积。

临床怎么用

  • 结果支持在增生性瘢痕治疗中探索MSC CM与Botox联合方案,但临床转化前需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both mesenchymal stem cell-conditioned medium (MSC CM) and Botox have demonstrated therapeutic effects for hypertrophic scar (HS). It is unclear whether a synergistic effect occurs when these treatments are used in combination. We aimed to investigate the therapeutic effects of MSC CM and Botox alone when compared with those of a combined regimen on HS. METHODS: Fibroblasts from human HS were isolated and treated with Dulbecco's modified Eagle's medium (DMEM), MSCCM, or Botox alone or a combination of MSCCM and Botox. We also used an in vivo HS-buried null mice model to investigate the efficacy of combination treatment. RESULTS: The results demonstrated that the combination of MSC CM and Botox downregulated both mRNA and protein levels of type I collagen, type III collagen, and alpha-smooth muscle actin (α-SMA) in HS fibroblasts. The combined regimen also suppressed fibroblast proliferative activity, increased apoptosis, and displayed significant inhibitory effects on the contractile ability of HS fibroblasts compared to MSC CM, Botox, or DMEM alone. Using an in vivo HS-buried null mice model, significant scar weight reduction, cell apoptosis, and less α-SMA expression were observed from the combined regimen of MSC CM and Botox compared to those from the other groups. The combined regimen also significantly improved arrangement and deposition of collagen fibers. CONCLUSIONS: This study demonstrates that a combination of MSC CM and Botox exhibited a significant therapeutic effect compared to monotherapy. Clinical translation of this therapy should be further considered.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Hu CH, Tseng YW, Lee CW, et al. Combination of mesenchymal stem cell-conditioned medium and botulinum toxin type A for treating human hypertrophic scars. J Plast Reconstr Aesthet Surg. 2019. PMID: 31488377. doi:10.1016/j.bjps.2019.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。